Are You Prepared? WHO Just Revealed 3 New Flu Strains for This Fall—What You MUST Know to Stay Safe!

The World Health Organization (WHO) has recommended a significant overhaul of the influenza vaccines for the upcoming Northern Hemisphere flu season, urging vaccine manufacturers to update the three viral strains included in the shots. This shift comes in response to the emergence of a new variant of the influenza virus, known as influenza A(H3N2) subclade K, which saw an uptick in cases last fall—after the current flu vaccines had already been produced and distributed.

According to Dr. Danuta Skowronski, a flu researcher at the British Columbia Centre for Disease Control, the late discovery of this new variant led to a mismatch between the vaccines people received this winter and the viruses circulating in the community. With current vaccine production methods requiring at least six months for preparation, companies need to act swiftly to incorporate these changes in time for immunization campaigns, which typically begin in late summer or early fall.

This issue isn't unique to the Northern Hemisphere; the WHO noted that the influenza A(H3N2) variant also emerged too late to be included in vaccines for the Southern Hemisphere, which runs its flu season from April to October. The WHO's recommendations include updates to not only the H3N2 strain but also two other strains that will be part of the fall flu shots.

Effectiveness of Current Vaccines

In a twist that surprised many public health experts, the current flu vaccines proved to be more effective than anticipated against subclade K. An interim report from researchers found that the latest flu vaccines in Canada reduced the risk of illness caused by A(H3N2) viruses by 40% for those vaccinated, compared to individuals who remained unvaccinated. Specifically, the vaccine demonstrated a 37% effectiveness against infections from subclade K that were serious enough to require outpatient medical visits, and a 31% effectiveness against the H1N1 strain.

The WHO's recommendations come at a pivotal time, being the first since the United States, historically a major funder and contributor to the WHO, exited the organization on January 22. The U.S. has provided over $680 million annually to the WHO, and experts are closely monitoring how this withdrawal may impact future public health initiatives.

Nonetheless, CDC scientists participated virtually in the WHO meeting held in Istanbul, Turkey, underscoring the importance of global collaboration in combating infectious diseases. Dr. Daniel Jernigan, former head of the National Center for Emerging and Zoonotic Infectious Diseases at the CDC, emphasized the necessity of maintaining engagement with the WHO. He stated, “The vaccine updates reflect the importance of global collaboration in preventing infectious diseases—efforts that simply could not happen working alone.”

Despite concerns about the U.S. withdrawal, two of the vaccine strains recommended for the upcoming flu shots are based on viral samples from the United States, specifically from Missouri and Pennsylvania. This indicates continued involvement from U.S. scientists in the global effort to combat influenza. “This means we can be better protected against more recently circulating flu B viruses, especially in children,” Jernigan added.

Looking ahead, the U.S. Food and Drug Administration (FDA) typically aligns its flu vaccine recommendations with those of the WHO. The VRBPAC, the committee that advises the FDA on vaccine-related matters, is set to meet on March 12 to discuss flu shot recommendations for the fall. However, uncertainties remain regarding whether the FDA will adopt the WHO's updates without imposing new barriers on vaccine manufacturers.

Concerns are amplified by the presence of Robert F. Kennedy Jr., a long-time anti-vaccine activist and current HHS secretary, who has made various false claims about the flu shot. This environment of skepticism could influence public health policies and vaccine uptake moving forward.

The WHO has provided detailed recommendations for the strains to be included in the fall flu shots, differentiated by how the vaccines are manufactured. Traditional egg-based vaccines will incorporate:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;
• an A/Darwin/1454/2025 (H3N2)-like virus;
• a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

For cell culture-, recombinant protein-, or nucleic acid-based vaccines, the recommendations include:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;
• an A/Darwin/1415/2025 (H3N2)-like virus;
• a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

As global health experts prepare for the next flu season, the emphasis on timely adjustments to vaccine formulations highlights the dynamic nature of influenza viruses and the importance of international cooperation in vaccine development. The coming months will be crucial as health organizations strive to ensure that updated vaccines are available when needed.